Last week, the German-based VC firm Earlybird Health announced it closed a €173 million ($185.4
million) fund to finance companies in Europe across the healthcare sector including digital health, diagnostics, medical devices and biopharma.
With the new health fund, Earlybird is planning to strategically tie financing activity to companies
between the A and B series rounds where there is not a tremendous amount of financing.
So far, the fund has made several investments in the biotech sector, including in Grey Wolf
Therapeutics and Arecium Therapeutics, which were preclinical when Earlybird invested in them
but are now seeing more significant activity and starting clinical trials, Nasrallah noted
While Earlybird has focused on oncology companies, it is looking to potentially invest in cancer-
based startups. The firm is also interested in future investments in other biopharma sectors, such
as fibrosis and the central nervous system.
https://www.biospace.com/article/earlybird-health-hopes-to-get-the-worm-with-new-186m-vc-fund/
Don't miss out on the excitement! Reserve your spot at one of our upcoming events:
SCALE UP WITH WOLVES AND EUROPEAN CVC AWARDS
26 March 2024, Spielfeld Digital Hub, Germany + online
WOLVES SUMMIT CEE
8-9 May 2024, Copernicus Science Centre, Warsaw, Poland + online